The Immunosuppressive Fungal Metabolite Gliotoxin Specifically Inhibits Transcription Factor NF-κB

By Heike L. Pahl,* Beate Krauß,* Klaus Schulze-Osthoff,* Thomas Decker,† E. Britta-Mareen Traenckner,* Markus Vogt,*, Christina Myers,‡ Tom Parks,§ Paul Warring,‖ Arno Mühlbacher,‖ Armin-Peter Czernilofsky,‖ and Patrick A. Baeuerle*

From the *Institute of Biochemistry and Molecular Biology, Albert-Ludwigs-University, D-79104 Freiburg, Germany; †Vienna Biocenter, Institute for Microbiology and Genetics, A-1030 Vienna, Austria; the ‡Department of Inflammatory Diseases, Boehringer Ingelheim, Ridgefield, Connecticut 06877; the ‖Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory 2601, Australia; and §Boehringer Ingelheim Research Vienna, A-1120 Vienna, Austria

Summary
Opportunistic infections, such as aspergillosis, are among the most serious complications suffered by immunocompromised patients. Aspergillus fumigatus and other pathogenic fungi synthesize a toxic epipolythiodioxopiperazine metabolite called gliotoxin. Gliotoxin exhibits profound immunosuppressive activity in vivo. It induces apoptosis in thymocytes, splenocytes, and mesenteric lymph node cells and can selectively deplete bone marrow of mature lymphocytes. The molecular mechanism by which gliotoxin exerts these effects remains unknown. Here, we report that nanomolar concentrations of gliotoxin inhibited the activation of transcription factor NF-κB in response to a variety of stimuli in T and B cells. The effect of gliotoxin was specific because, at the same concentrations, the toxin did not affect activation of the transcription factor NF-AT or of interferon-responsive signal transducers and activators of transcription. Likewise, the activity of the constitutively DNA-binding transcription factors Oct-1 and cyclic AMP response element binding protein (CREB), as well as the activation of protein tyrosine kinases p56 lck and p59 fyn, was not altered by gliotoxin. Very high concentrations of gliotoxin prevented NF-κB DNA binding in vitro. However, in intact cells, inhibition of NF-κB did not occur at the level of DNA binding; rather, the toxin appeared to prevent degradation of IκB-α, NF-κB's inhibitory subunit. Our data raise the possibility that the immunosuppression observed during aspergillosis results in part from gliotoxin-mediated NF-κB inhibition.

Because of the development of intensive combination chemotherapy and bone marrow transplant preparatory regimens, both of which cause prolonged myelosuppression, the incidence of fungal infections in cancer patients has risen sharply in the past decades (1). Fungal infections are now the cause of death in 40% of patients with acute leukemia at some hospitals. In a recent international survey (2), 30% of mycotic infections represented cases of aspergillosis, which is caused by the fungi Aspergillus fumigatus, A. flavus, A. niger, and A. terreus. Aspergillosis carries a very high mortality rate, survival ranging only between 5 and 20%.

The precise molecular mechanism of Aspergillus pathogenesis remains unclear. One possible etiological agent is the secondary fungal metabolite gliotoxin. This metabolite is produced in large quantities by fungal cultures and can be isolated from mice undergoing systemic experimental aspergillosis (3). Gliotoxin belongs to the epipolythiodioxopiperazine class of compounds and is lethal at relatively low concentrations (LD50 in mice and rats: 25–50 mg/kg) (4). Gliotoxin exhibits profound immunosuppressive effects in vivo. Sublethally irradiated mice injected intraperitoneally with gliotoxin showed a significant delay in the recovery of immune cells compared with untreated irradiated controls (5). Whereas LPS-responsive B cells were detected by proliferation assays in control animals 14 d after irradiation, animals treated with a single dose of 100 μg gliotoxin showed no measurable B cell response until 30 d after irradiation. By contrast, the recovery of the T cell response, as measured by Con A–stimulated cell proliferation, was equal in both mock- and gliotoxin-treated animals. The in vivo data differ somewhat from observations in vitro, where gliotoxin inhibits mitogen-induced proliferation of both B and T cells. Furthermore, in MLCs, pretreatment of stimu-
Gliotoxin Inhibits NF-κB

Gliotoxin exerts its immunosuppressive effects in part by inhibiting activation and proliferation of B and T cells. We therefore investigated whether the toxin interferes with the activation of transcription factors that are crucially involved in B and T cell activation and proliferation: nuclear factor NF-κB, nuclear factor of activated T cells NF-AT, and signal transducer and activator of transcription (STAT) factors. NF-κB is a central mediator of the immune response. It regulates the transcription of various inflammatory cytokines, hematopoetic growth factors, growth factor receptors, and cell adhesion molecules (listed in detail in reference 10). In most cell types, NF-κB is sequestered in an inactive, cytoplasmic complex by binding to IκB, its inhibitory subunit. A large variety of T or B cell–activating stimuli rapidly induce NF-κB, stimulating κB-dependent transcription. Many NF-κB target genes encode proteins controlling cell proliferation. NF-κB activation requires phosphorylation and proteolytic degradation of IκB subunits. The active NF-κB complex, which translocates to the nucleus, is frequently composed of a heterodimer of p50 and RelA (p65) subunits. Whereas mouse null mutants of p50 are viable and show only a very weak immunodeficient phenotype, null mutants of RelA die in utero and show massive apoptosis in the liver. Mice lacking c-rel are defective in lymphocyte proliferation, humoral immunity, and IL-2 expression. Pharmacological inhibition of NF-κB in vivo may thus affect immune regulation as well as cell survival.

The NF-AT family of transcription factors, whose members share weak sequence similarity with NF-κB/Rel proteins, also plays an important role in T cell activation. These proteins regulate the expression of the genes for IL-2, -3, -4, GM-CSF, and TNF-α. Activation of cytoplasmic NF-AT factors requires the calcium- and calmodulin–dependent phosphatase calcineurin, nuclear translocation of NF-AT, and the association of NF-AT with an AP-1 factor on the DNA (for reviews see references 22, 23). The importance of NF-AT in T cell activation is illustrated by the effect of the fungal metabolites cyclosporin A and FK506. These agents indirectly inhibit calcineurin thereby preventing NF-AT activation (24, 25). Treatment of patients with cyclosporin A or FK506 causes a potent immunosuppression that is exploited clinically for organ transplantation (26–28). Natural immunosuppressive compounds with specificity for NF-κB have not yet been reported.

Stimulation of cells in response to IFNs is mediated by the STAT family of transcription factors. Like NF-AT and NF-κB/Rel proteins, STATs are maintained in a cytoplasmic form in unstimulated cells (29). STAT activation occurs via direct phosphorylation by receptor-associated tyrosine kinases, subsequent dimerization via SH2 domains, and nuclear translocation (30). Stimulation of cells with type I IFN (IFN-α/β) causes activation of STAT1 and STAT2, which subsequently form a transcription factor, ISGF3, which consists of a STAT1-STAT2 heterodimer in association with a 48-kD DNA-binding protein. This 48-kD subunit belongs to the IRF family of proteins. ISGF3 activates transcription of target genes like MHC class I by associating with a promoter DNA sequence designated the interferon-stimulated response element (ISRE). In contrast, type II IFN (IFN-γ) exclusively activates STAT1 so that a homodimer is formed that binds to a distinct response element, the gamma interferon activation site (GAS; 30). Other cytokines and growth factors, including prolactin, epidermal growth factor, IL-2, -3, -4, -6, -12, LIF, erythropoietin, and growth hormone also use members of the STAT factor family as signal transducers (31–36). We show here that nanomolar concentrations of gliotoxin specifically inhibited the activation of NF-κB in various cell types, whereas the activation of NF-AT and STAT factors was not affected at such low concentrations. The toxin prevented stimulation of κB–controlled reporter gene activity by TNF, IL-1, and PMA whereas it did not affect induction in response to IFN-γ. NF-κB activation in response to five different stimuli (LPS, IL-1β, TNF-α, PMA/PHA, and okadaic acid) was blocked, suggesting that gliotoxin interfered with a late step in a common signaling cascade leading to NF-κB activation. Very high concentrations of gliotoxin inhibited NF-κB DNA binding in vitro, most likely because of oxidation of a cysteine residue by the toxin’s sulphydryl group. However, this modification did not occur in vivo: overexpressed p50 and cytoplasmic NF-κB complexes with IκB were not inactivated by the toxin. Inhibition of NF-κB activation most likely results from inhibition of IκB-α proteolysis. Our data suggest that the immunosuppressive activity of the fungal metabolite gliotoxin may rely on inhibition of the transcription factor NF-κB in T and B cells.

Materials and Methods

Cell Culture

Jurkat, 70Z/3, D10.G4.1, and stably transfected A549 cells were maintained in RPMI 1640 medium; HeLa S3 and 293 cells.
were maintained in DMEM. Both were supplemented with 10% FCS and 50 μg/ml penicillin-streptomycin (all from Gibco BRL, Eggenstein, Germany). Medium for D10.G4.1 cells contained 50 μg/ml β-ME and 50 U/ml IL-2 in addition. The 70Z/3 cells transfected with the p55 TNF receptor were generously given by Dr. M. Krönke (Kiel, Germany); gliotoxin, methyl-thiogliotoxin (bis-dethio-bis(methylthio)-gliotoxin), PMA, and LPS were purchased from Sigma Chemical Co. (Münich, Germany). Other chemicals were obtained from the following suppliers: okadaic acid (Paesel and Lorei GmbH & Co., Hanau, Germany), IL-1β (Genzyme Corp., Cambridge, MA) and TNF (Boehringer-Mannheim, Mannheim, Germany).

**Transfections**

293 cells were plated 12–16 h before transfection at a density of 10⁶ cells per 60-mm dish. Transfections were performed using calcium phosphate precipitation as previously described (16).

**Transactivation Assays**

A549 cells, stably transfected with the plasmid pGL3H carrying a luciferase reporter gene driven by a fragment of the intercellular adhesion molecule (ICAM) 1 promoter (bp 277 to −9 relative to the start of transcription) carrying response elements for both TNF-α and IFN-γ (37–39), were seeded in microtiter plates. Cells were pretreated with either 1 μg/ml gliotoxin or 3 μg/ml bis-dithio-bis(methylthio)-gliotoxin for 30 min before stimulation with either 300 U/ml TNF-α, 1 ng/ml IL-1ß, 20 ng/ml PMA, or 300 U/ml IFN-γ for 6 h. Cells were harvested in situ using a commercial lysis buffer and luciferase assay system (Promega Corp., Heidelberg, Germany) and luciferase activity was determined on a microplate scintillation counter (TopCount; Packard Instruments Co., Inc., Meriden, CT).

**Plasmids**

The expression vector containing amino acids 1–399 of the NF-κB p50 subunit has been previously described in detail (40).

**Electrophoretic Mobility Shift Assays**

**NF-κB, Oct-1, and CREB.** Total cell extracts were prepared using a high salt detergent buffer (Totex buffer) (20 mM Hepes, pH 7.9, 350 mM NaCl, 20% (vol/vol) glycerol, 1% (wt/vol) NP-40, 1 mM MgCl₂, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 mM dithiothreitol [DTT], 0.1% PMSF, and 1% aprotinin). Cells were harvested by centrifugation, washed once in ice-cold PBS (Sigma) and resuspended in four cell volumes of Totex buffer. The cell lysate was incubated on ice for 30 min, then centrifuged for 5 min at 13,000 g at 4°C. The protein content of the supernatant was determined and equal amounts of protein (10–20 μg) were added to a reaction mixture containing 20 μg BSA (Sigma), 2 μg poly (dl-dC) (Boehringer Mannheim), 2 μl buffer D* (20 mM Hepes, pH 7.9, 20% glycerol, 100 mM KCl, 0.5 mM EDTA, 0.25% NP-40, 2 mM DTT, and 0.1% PMSF), 4 μl buffer F (20% Ficoll-400, 100 mM Hepes, 300 mM KCl, 1 mM DTT, 0.1% PMSF), and 100,000 cpm (Cerenkov Counting) of a 32P-labeled oligonucleotide in a final volume of 20 μl. Samples were incubated at room temperature for 25 min. NF-κB, CREB, and Oct-1 oligonucleotides (Promega) were labeled using γ-[32P]ATP (3,000 Ci/mmol; Amrenham International, Braunschweig, Germany) and T4 polynucleotide kinase (Promega).

**DOC Activation.** DOC activation was performed precisely as previously described (11); the detergent (purchased from Sigma) was added to a final concentration of 0.4%.

**NF-AT.** Nuclear extracts were prepared as previously described (41). Electrophoretic mobility shift assay (EMSA)-binding reactions were identical to those used for NF-κB, Oct-1, and CREB except that only 0.2 μg/ml poly (dl-dC) was used.

**STAT Factors**

ISGF3 activation was determined in an EMSA using the ISRE from the promoter of the ISG15 gene (42) as a probe. HeLa S3 cells were treated for 12 h with 1 ng/ml IFN-γ followed by a 30-min stimulation with 1,000 U/ml of IFN-α before harvest. Where indicated, gliotoxin was added 30 min before addition of IFN-α and remained in the culture medium during IFN stimulation. The EMSA conditions have been described previously (29). For in vitro treatment of ISGF3 with gliotoxin, the extracts were treated with the indicated concentrations of the drug for 30 min at room temperature before addition to the EMSA-binding reaction.

**Immunoprecipitation and Kinase Assays**

Jurkat cells (2 × 10⁷) were pretreated with different concentrations of gliotoxin for 1 h and subsequently stimulated with 50 ng/ml PMA for 30 min. Cells were washed with ice-cold PBS containing 400 μM EDTA and 400 μM sodium vanadate and lysed in 250 μl of RIPA buffer (5 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 100 μM Na₃VO₄, 1 mM DTT, 1 mM PMSF, 10 μg/ml leupeptin, and 10 mM sodium phosphate, pH 7.4). Nuclei and cell debris were removed by centrifugation at 16,000 g for 15 min at 4°C. The supernatant was precleared with protein A-Sepharose (Pharmacia LKB, Freiburg, Germany) and immunoprecipitated with 1 μg of rabbit anti-p56Lck or anti-p59cyt antibody (Upstate Biotechnology, Inc., Lake Placid, NY). Immune complexes were collected with protein A-Sepharose and washed twice with lysis buffer, once with 10 mM Hepes, pH 8.0, containing 50 mM NaCl, and once with Hepes buffer without NaCl. Immune complex kinase assays were performed by incubation at 25°C in 50 μl kinase buffer (30 mM Hepes, pH 7.2, 5 mM MgCl₂, 5 mM MnCl₂, 1 mM ATP, and 10 μCi γ-[32P]ATP) containing 5 μg of acid-treated rabbit muscle enolase (Sigma). After 15 min, the reaction was ended by the addition of Laemmli buffer. The samples were analyzed by 10% SDS-PAGE and subjected to autoradiography.

**Western Blotting**

Total cell extracts (100 μg) were boiled in Laemmli sample buffer and subjected to SDS-PAGE. Before transfer, gels were equilibrated in ice-cold blotting buffer (48 mM Tris, 39 mM glycine, 15% methanol, and 0.037% SDS). Proteins were transferred at 2.5 mA/cm² for 1 h onto Immobilon P membranes (Millipore Corp., Eschborn, Germany) using a semi-dry blotting apparatus (Bio-Rad Laboratories, Munich, Germany). Transfer efficiency was monitored by Ponceau S staining of membranes. Nonspecific binding sites were blocked by immersing the membrane in TBST blocking solution (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20 [vol/vol]) containing 5% low-fat dried milk powder) overnight at 4°C. After a short wash in TBST, the membranes were incubated in a 1:700 dilution of anti-IκBα antibody (12) in blocking solution for 1 h at room temperature, followed by extensive washing with TBST. Bound antibody was decorated with goat anti-rabbit/horseradish peroxidase conjugate (Bio-
Rad; diluted 1:3,000 in blocking solution) for 30 min at room temperature. After washing for 45 min, the immunocomplexes were detected using enhanced chemiluminescence Western blotting reagents (ECL; Amersham). Exposure to Eastman Kodak XAR-5 film (Rochester, NY) was performed for 30 s.

**Results**

**Gliotoxin Is a Potent Inhibitor of NF-κB Activation.** To investigate whether gliotoxin interferes with the activation of transcription factors involved in T cell activation, Jurkat T cells were incubated with various concentrations of gliotoxin.
for 1 h. Subsequently, cells were stimulated for 1 h with PMA/PHA, after which total cell extracts were prepared. The extracts were analyzed for NF-κB DNA-binding activity in an EMSA. Stimulation with PMA/PHA induced one novel DNA-binding activity in Jurkat T cells (Fig. 1 A, lane 2). Antibody reactivity and competition assays identified this complex as a NF-κB p50/p65 heterodimer (data not shown; 15, 43). NF-κB activation was significantly reduced by treatment of Jurkat cells with 70 ng/ml of gliotoxin, whereas 100 ng/ml (300 nM) gliotoxin and higher concentrations completely prevented NF-κB induction (Fig. 1 A, lanes 7 and 8). The weak basal activity of NF-κB (lane 1) was not reduced even at very high gliotoxin concentrations (lanes 10–14), indicating that the toxin did not directly inhibit NF-κB DNA binding. A very similar dose–response was observed in the HeLa tumor cell line as well as in various other cell lines (see below; data not shown). A faster migrating, nonspecific DNA-binding activity was not altered by gliotoxin treatment, even when doses ≤50 μg/ml were used (Fig. 1 A, lane 14).

We analyzed the Jurkat T cell extracts shown in Fig. 1 A in EMSAs using DNA probes containing consensus motifs for the constitutively bound transcription factors Oct and CREB (Fig. 1 B). Treatment with gliotoxin concentrations ≤50 μg/ml did not detectably affect DNA binding of Oct and CREB proteins to their respective DNA probes. Taken together, these data show that treatment of cells with gliotoxin at nanomolar concentrations specifically inhibits the activation of transcription factor NF-κB, whereas the DNA-binding activity of other transcription factors remained unaffected at up to 500-fold higher concentrations.

Gliotoxin Is an Inhibitor of NF-κB–dependent Gene Expression. The inducible expression of the ICAM-1 gene in response to TNF-α, IL-1β, and PMA is controlled by a NF-κB–binding site in its upstream promoter, whereas the inducibility in response to IFN-γ is controlled by a binding motif for STAT1 (37–39). Here, we tested the effect of gliotoxin on the expression of a stably integrated firefly luciferase reporter gene under control of a fragment of the human ICAM-1 promoter in A549 cells (37). As shown in Fig. 2, TNF-α, IL-1β, PMA, and IFN-γ caused a substantial induction of the reporter gene. 1 μg/ml gliotoxin, which did not affect the basal ICAM-1 promoter activity, suppressed reporter gene induction by TNF-α, IL-1β, and PMA, which act via the κB motif. By contrast, gliotoxin could not suppress induction of the ICAM-1 promoter by IFN-γ, which is mediated by STAT transcription factors. These data provide compelling evidence for the specificity of the toxin. The inhibitory activity of gliotoxin on κB-dependent gene expression relied on intact sulfhydryl groups; 3 μg/ml of the immunologically inactive derivative methylthiogliotoxin (44, 45) did not display any inhibitory potential (Fig. 2). At higher concentrations of gliotoxin, inhibitory as well as stimulatory effects on the activity of vari-

![ICAM-1](image.png)

**Figure 2.** The effect of gliotoxin on ICAM-1 promoter-driven reporter gene activity. A549 cells stably transfected with a luciferase reporter gene driven by a fragment of the ICAM-1 promoter were treated for 30 min with either 1 μg/ml gliotoxin or 3 μg/ml methyl gliotoxin as indicated. Subsequently, cells were induced with either 300 U/ml TNF-α, 1 ng/ml IL-1β, 20 ng/ml PMA, or 300 U/ml IFN-γ for 6 h and luciferase activity was determined. The results are given in arbitrary relative light units and are representative of three experiments.
ious unrelated promoters and enhancers were observed in reporter gene assays (data not shown), suggesting that only low concentrations of gliotoxin specifically affected NF-κB. Functional analysis of the ICAM-1 promoter thus corroborates data obtained from EMSAs showing that nanomolar concentrations of gliotoxin potently and specifically inhibit NF-κB activation.

Gliotoxin Does Not Impair Activation of STAT and NF-AT Factors. To further investigate the specificity of gliotoxin, we studied the activation of STAT and NF-AT factors by IFNs and PMA/ionomycin, respectively. The effect of gliotoxin on the activation of STAT factors was tested in HeLa S3 cells. In these cells, NF-κB activation is also inhibited by pretreatment with 100 ng/ml of gliotoxin (data not shown). Extracts from control or IFN-α/γ-pretreated cells were assayed in an EMSA using an ISRE as the DNA probe (Fig. 3 A). Pretreatment of HeLa S3 cells with IFN-γ for 12 h increases the amount of the 48-kD DNA-binding subunit of ISGF3 (p48) and therefore the amount of ISGF3 generated after a subsequent pulse with IFN-α (46). Moreover, under these conditions, elevated amounts of ISGF2/IRF1, another ISRE-binding factor, are observed. Since induction of the ISGF2/IRF1 gene by IFN depends on STAT1 binding to a GAS sequence in the IRF1 promoter (47), these conditions also determine whether STAT1 homodimer activation is intact. Doses of ≤10 μg/ml gliotoxin did not significantly perturb the activation of STAT1, STAT2, IRF-2, and p48 in response to IFN-α/γ stimulation of HeLa S3 cells (Fig. 3 A, lanes 4–7). Similarly, treatment of extracts from IFN-α/γ-stimulated HeLa S3 cells with gliotoxin under cell-free conditions had no effect on the DNA-binding of these factors (Fig. 3 B).

D10.G4.1 T cells behaved similarly to Jurkat T cells with respect to the inhibition of NF-κB activation by gliotoxin (data not shown). In nuclear extracts of these cells, treatment with PMA/ionomycin strongly induced an activity that binds to the distal NF-AT site in the murine IL-2 enhancer (Fig. 4, compare lanes 1 and 2). This protein–DNA complex is specifically competed by an excess of unlabeled oligonucleotide (data not shown). T cells were treated for 1 h with increasing concentrations of gliotoxin followed by a 1-h stimulation with PMA/ionomycin. Activation of NF-AT from its cytoplasmic form was not affected by a treatment of D10.G4.1 T cells with gliotoxin, even at a concentration of 10 μg/ml, 100-fold the concentration that abrogated activation of NF-κB (see Fig. 1). As seen

Figure 3. The effect of gliotoxin on DNA binding of STAT factors in vitro and in vivo. (A) HeLa S3 cells were treated in vivo for 12 h with IFN-γ and subsequently with IFN-α for 30 min. The indicated concentrations of gliotoxin were added 30 min before addition of IFN-α and remained in the culture medium during IFN stimulation. Equal amounts of protein from whole cell extracts were analyzed for STAT factor binding by EMSA. (Lane 7) A 100-fold excess of unlabeled oligonucleotide was added as a competitor. A section of a fluorogram is shown. (B) Positions of various STAT factor DNA complexes. (B) Unstimulated HeLa S3 cells (lane 1) or cells stimulated with IFN-γ and IFN-α as described for A (lanes 2–7) were used to prepare whole cell extracts. The extracts were treated with various concentrations of gliotoxin in vitro as indicated. Equal amounts of protein from cell extracts were analyzed for STAT factor binding by EMSA. (Lane 7) A 100-fold excess of unlabeled oligonucleotide was added as a competitor. A section of a fluorogram is shown. (B) Positions of various STAT factor DNA complexes.
Figure 4. The effect of gliotoxin on NF-AT DNA binding. D10.G4.1 cells were treated for 1 h with gliotoxin at the concentrations indicated and were subsequently stimulated with 50 ng/ml PMA and 1 μM ionomycin for 1 h. (Lane 1) Unstimulated control cells were used. Equal amounts of protein from nuclear extracts were analyzed for NF-AT activity by EMSA. (▲) Position of NF-AT DNA complexes. (▼) Unbound oligonucleotide.

In previous experiments (Figs. 1–3), none of the unrelated nonspecific DNA-binding activities was sensitive towards gliotoxin. Taken together, these data show that treatment of cells with gliotoxin specifically inhibits the activation of transcription factor NF-κB whereas other constitutive and inducible factors remain unaffected at up to 500-fold higher concentrations. In the following, we examined several steps in the signal transduction pathway, which lead to NF-κB activation in B and T cells, for their susceptibility to gliotoxin.

Gliotoxin Acts on a Common Mechanism of NF-κB Activation. NF-κB can be activated by numerous stimuli (10). Reporter gene assays using the ICAM-1 promoter (Fig. 2) showed that gliotoxin inhibits NF-κB activation in response to several different stimuli, suggesting that the toxin targets a signal transduction step shared by many inducers. To test this hypothesis, we used the pre-B cell line 70Z/3, in which NF-κB can be activated by such diverse stimuli as PMA, LPS, IL-1β, or the phosphatase 2A inhibitor okadaic acid. In a stably transfected 70Z/3 clone carrying the p55 TNF receptor (48), NF-κB can also be induced with TNF-α. 70Z/3 or 70Z/3-p55 cells were preincubated with 1 μg/ml of gliotoxin for 1 h before stimulation with the various NF-κB inducers. The stimuli induced NF-κB DNA-binding activity to different levels (Fig. 5). Pretreatment with gliotoxin completely prevented the activation of NF-κB by all five stimuli, indicating that the toxin interfered with a common event shared by all inducers.

Only Very High Concentrations of Gliotoxin Inactivate NF-κB DNA Binding. A simple explanation for the inhibitory effect of gliotoxin would be a direct interference with the DNA-binding assay detecting NF-κB. Gliotoxin is a sulfhydryl compound with the potential to covalently modify proteins by formation of mixed disulfides with exposed cysteine residues (3). NF-κB subunits harbor a redox-sensitive cysteine residue in their DNA-binding domains (49–51). In addition, gliotoxin has been shown to cause DNA breaks at 90 μg/ml in vitro (52), such that high gliotoxin concentrations may impair DNA-binding reactions by damaging the oligonucleotide probe. To test these possibilities, we incubated cell extracts from PMA/PHA-activated Jurkat T cells containing activated NF-κB with gliotoxin. Addition of 25 μg/ml gliotoxin to the DNA-binding reaction did not detectably inhibit NF-κB DNA binding in vitro (Fig. 6, lane 3). Only concentrations ≥250 μg/ml impaired DNA binding of NF-κB (Fig. 6, lanes 4 and 5).

It is possible that in intact cells gliotoxin is converted into a metabolite that directly modifies NF-κB. We investigated this hypothesis by transfecting 293 cells with an expression vector for the p50 DNA-binding subunit of NF-κB. p50 was previously shown to be highly susceptible to modification of Cys62 by oxidants (49, 51). Overexpressed p50 is not subject to significant IkB inactivation and will therefore constitutively bind DNA as a homodimer (53). Transfected 293 cells expressing p50 NF-κB were treated with increasing concentrations of gliotoxin for 2 h after which cell extracts were analyzed by EMSA. Concentrations of ≤50 μg/ml gliotoxin, 500-fold the inhibitory dose for NF-κB activation, did not impair the p50 DNA-binding activity in vivo (Fig. 7). In addition, we found that the NF-κB/IκB complex in nonstimulated 70Z/3 pre-B cells, was not inactivated by gliotoxin treatment; deoxycholate treatment (11) recovered similar amounts of NF-κB activity in cell extracts from control and gliotoxin-treated cells (Fig. 8, compare lanes 2 and 4). Taken together, these data suggest that gliotoxin does not directly modify NF-κB DNA-binding subunits in vivo.

Gliotoxin Does Not Prevent Activation of Tyrosine Kinases p56lck or p59fyn upon T Cell Activation. An early event after stimulation of the TCR is the activation of the Src-like tyrosine kinases p56lck and p59fyn (54, 55). Extracts from control and gliotoxin-treated Jurkat T cells were used for immunoprecipitation with antibodies against p56lck or p59fyn. Kinase activities were determined by incubation of immunoprecipitates with the substrate rabbit muscle enolase and γ-[32P]ATP. Tyrosine-phosphorylated enolase was then separated by SDS-PAGE and visualized by autoradiography.
Figure 5. The effect of gliotoxin on NF-κB activation in response to five distinct stimuli. 70Z/3 pre-B cells were stimulated with 50 ng/ml PMA (lanes 2 and 9), 50 U/ml of IL-1-β (lanes 3 and 10), or 10 μg/ml of LPS (lanes 4 and 11). A stably transfected 70Z/3 clone, expressing the p55 TNF receptor, was stimulated with 200 U/ml of TNF (lanes 6 and 13) or 0.5 μM okadaic acid (lanes 8 and 14). In lanes 1, 5, 8, and 12 the appropriate unstimulated control cells were used. The cells analyzed in lanes 8–14 were pretreated with 1 μg/ml gliotoxin for 1 h before stimulation. Equal amounts of protein from cell extracts were analyzed for NF-κB activity by EMSA. A section of a fluorogram is shown. (▲) Position of NF-κB DNA complexes. (O) A nonspecific activity binding to the probe; (<3) unbound oligonucleotide.

Figure 6. The effect of gliotoxin on NF-κB DNA binding. Extracts from PMA/PHA-stimulated Jurkat cells were analyzed for NF-κB DNA binding by EMSA. The indicated amounts of gliotoxin were added to the EMSA-binding reactions in vitro.

Figure 7. The effect of gliotoxin on p50 DNA binding. 293 cells were transiently transfected with 6 μg of a p50 expression vector. 24 h after transfection, cells were treated with various concentrations of gliotoxin, as indicated, for 2 h. Total cell extracts were prepared and analyzed by EMSA using a 32P-labeled oligonucleotide probe containing a NF-κB-binding site. A section of a fluorogram is shown. (▲) The NF-κB p50 homodimer DNA complex. (O) Unbound oligonucleotide.

Gliotoxin Allows IKK-α Phosphorylation but Prevents Its Degradation. Release of IKK-α from NF-κB requires phosphorylation of IKK-α on serines 32 and 36 and subsequent proteolytic degradation of IKK-α by the ubiquitin/proteasome pathway (12–16). The inducible phosphorylation of
Figure 8. Activation of NF-kB DNA binding by DOC sodium deoxycholate treatment. 70Z/3 pre-B cells were treated with 1 μg/ml gliotoxin (lanes 3 and 4) or left untreated (lanes 1 and 2). In lanes 2 and 4 the detergent DOC was added to cell extracts for 15 min to a final concentration of 0.4%. Subsequently, the cell extracts were analyzed for NF-kB activity by EMSA. A section of a fluorogram is shown. (1) Position of NF-kB DNA complexes. (2) A nonspecific activity binding to the probe. IκB is readily detected in Western blots as a slight decrease in protein mobility. Jurkat T cells were treated with gliotoxin for 1 h and stimulated with 0.5 μM okadaic acid for 60 min. IκB-α was detected on Western blots using a polyclonal antibody (12). In control cells, okadaic acid stimulation led to a decreased mobility of IκB-α and a reduction in the total amount of IκB (Fig. 10, top, lane 2), which coincided with NF-kB activation in EMSAs (bottom, lane 2). In gliotoxin-treated cells, the inducible mobility decrease of IκB-α in response to okadaic acid is still observed (Fig. 10, top, lane 4), indicating that the toxin did not inhibit the IκB-α kinase. However, more phosphorylated IκB-α was present and, consequently, less NF-kB activated (Fig. 10, bottom, lane 4) than under control conditions (compare lanes 2 and 4), suggesting that gliotoxin interfered with IκB-α degradation.

Discussion
Invasive aspergillosis represents one of the most difficult therapeutic problems in immunocompromised patients. Despite therapy with the antifungal agent Amphotericin B, mortality rates range between 75 and 100% (56). This challenge is compounded by the lack of knowledge about the molecular mechanism of Aspergillus pathology. The secondary fungal metabolite gliotoxin, synthesized by A. fumigatus and other pathogenic fungi, can be isolated from peritoneal lavages of mice undergoing systemic experimental aspergillosis (3). To date, however, gliotoxin has not been implicated directly in the pathogenesis of aspergillosis and its mechanism of action remains a matter of debate (57, 58).

We show here that gliotoxin inhibits the activation of transcription factor NF-kB, a central mediator of the human immune response. NF-kB activates the transcription of various cytokine genes including those for IL-1, IL-2, GM-CSF, G-CSF, M-CSF, and IL-6 (10). Gliotoxin inhibits

Figure 10. The effect of gliotoxin on IκB-α phosphorylation and proteolytic degradation. Jurkat T cells were treated with 1 μg/ml gliotoxin for 1 h before stimulation with 0.5 μM okadaic acid for 60 min. (Top) Cell extracts were analyzed by SDS-PAGE and Western blotting with an anti-IκB-α polyclonal antibody. (Bottom) Extracts were analyzed for NF-kB activity by EMSA. A section of a fluorogram is shown. (1) Position of NF-kB DNA complexes and nonspecific binding to the DNA probe (n.s.)
IL-1 synthesis in macrophages and the release of IL-2 from activated T cells (6, 59). These effects can now be explained by the inhibition of NF-κB activation. Similarly, gliotoxin treatment of stimulator cells prevents the induction of alloreactive cytotoxic T cells in MLCs. This most likely results from the loss of NF-κB-mediated IL-2 expression (60), since the inhibition can be overcome by the exogenous addition of IL-2. Gliotoxin’s inhibition of mitogen-activated T and B cell proliferation (45) may also be a consequence of NF-κB inhibition. NF-κB is induced by many B and T cell mitogens such as LPS, Con A, anti-CD28, anti-CD3, anti-IgM, and lymphotrophic viruses (10). By inhibiting NF-κB activation, gliotoxin may interrupt one signal transduction pathway leading to T and B cell proliferation. The selective delay in the recovery of LPS-responsive B cells in gliotoxin-treated mice (5) can be explained in the same manner.

The mechanism of action by which gliotoxin exerts its effect remains a matter of debate. It has been shown that gliotoxin causes DNA fragmentation in vitro and in vivo. In vivo, treatment of L929 fibroblasts, a sheep squamous cell carcinoma line, macrophages, or spleen cells with 30 ng–1 μg/ml of gliotoxin for 1 h causes DNA fragmentation (9). Other cell types, for example the monkey kidney cell line Vero, the rat mammary carcinoma MAT, or the mouse mastocytoma cell line P815 are resistant to gliotoxin-induced DNA damage. In vitro, gliotoxin shows no effect on DNA on its own; high concentrations of the toxin (0.3 mM or 90 μg/ml) need to be incubated with reductants such as DTT or glutathione in order to produce DNA damage (52).

Eichner et al. (52) proposed that the DNA damage is caused by the production of H₂O₂ through redox-cycling of gliotoxin. In this model, gliotoxin undergoes intracellular processing to the dithiol derivative, generating a redox cycle that produces superoxide anions and ultimately, H₂O₂. This hypothesis has been contradicted by Schweizer and Richter (57), who find no evidence for either redox-cycling or H₂O₂ production by gliotoxin in isolated mitochondria. Rather, they propose that gliotoxin reacts with thiol groups to cause a transient release of Ca²⁺ from mitochondria. Contrary to this report, Beaver and Waring (58) found no increase in intracellular Ca²⁺ levels when thymocytes were treated with concentrations of gliotoxin between 50 nM and 10 μM. Only doses >500 mM produced large increases in intracellular Ca²⁺ levels.

Based on the data presented in this paper, we propose a new model for the mechanism of action of gliotoxin. We suggest that gliotoxin’s effects on immune cells are mainly due to the inhibition of NF-κB activation. An inability to activate NF-κB is also achieved in transgenic mice, which carry a deletion in the gene for the p65 subunit of NF-κB. These animals die in utero and show severe apoptosis in the liver (19). It is interesting to note that mice treated with gliotoxin show extensive apoptosis in spleen cells by light and electron microscopy and by DNA fragmentation analysis (5). Both the fetal liver and the adult spleen are hematopoietic organs. Perhaps certain hematopoietic cells require the ability to activate NF-κB in order to avoid programmed cell death. Spleens from gliotoxin-treated mice are selectively depleted of B cells (5). FACS® analysis performed 16 d after gliotoxin treatment identified 37% of the splenocytes as B cells whereas in control animals, 70% of the population were stained with a B cell marker. It appears that the inability to activate NF-κB leads to apoptosis in B cells.

We propose the following model for the mechanism of action of the fungal metabolite gliotoxin. By inhibiting activation of the transcription factor NF-κB, gliotoxin abrogates B and T cell stimulation, causing a severe immunosuppression. Furthermore, the inability to activate NF-κB may cause apoptosis of B cells, compounding the immunosuppressive effect. Our data suggest a direct role for gliotoxin in the pathology of Aspergillosis.

We thank Elmar Böhm for excellent technical assistance.

This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ba-957/1-3) and the European Community Biotechnology Programme to P.A. Baeuerle.

Address correspondence to Dr. Heike L. Pahl, Institute of Biochemistry, Albert-Ludwigs University, Hermann-Herder-Str. 7, D-79104 Freiburg, Germany. Dr. Baeuerle’s present address is Tularik Inc., South San Francisco, CA 94080.

Received for publication 17 November 1995.

References
1. Bodey, G.P. 1988. The emergence of fungi as major hospital pathogens. J. Hosp. Infect. 11:411-426.
2. Bodey, G., B. Bueltmann, W. Duguid, D. Gibbs, H. Hanak, M. Hotchi, G. Mall, P. Martino, F. Meunier, S. Milikien et al. 1992. Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis. 11:99-109.
3. Waring, P., R.D. Eichner, and A. Mühlbacher. 1988. The chemistry and biology of the immunomodulating agent gliotoxin and related epipolythiodioxopiperazines. Med. Res. Rev. 8:499-524.
4. Taylor, A. 1971. The toxicology of sporidesmin and other epipolythiodioxopiperazines. Microbiol. Toxins. 7:337-376.
5. Sutton, P., N.R. Newcombe, P. Waring, and A. Mühlbacher. 1994. In vivo immunosuppressive activity of gliotoxin, a me-
tabolite produced by human pathogenic fungi. *Infect. and Immun.* 62:1192–1198.
6. Müllbacher, A., and R.D. Eichner. 1984. Immunosuppression in vitro by a metabolite of a human pathogenic fungus. *Proc. Natl. Acad. Sci. USA.* 81:3835–3837.
7. Waring, P., M. Egan, A. Braithwaite, A. Müllbacher, and A. Sjaarda. 1990. Apoptosis induced in macrophages and T blasts by the mycotoxin sporidesmin and protection by Zn2+ salts. *Int. J. Immunopharmacol.* 12:445–457.
8. Waring, P., E.R. D., A. Müllbacher, and A. Sjaarda. 1998. Gliotoxin induces apoptosis in macrophages unrelated to its antipagocytic properties. *J. Biol. Chem.* 263:18493–18499.
9. Braithwaite, A.W., R.D. Eichner, P. Waring, and A. Müllbacher. 1987. The immunomodulating agent gliotoxin causes genomic DNA fragmentation. *Mol. Immunol.* 24:47–55.
10. Baueuerle, P.A., and T. Henkel. 1994. Function and activation of NF-kB in the immune system. *Annu. Rev. Immunol.* 12:141–179.
11. Baueuerle, P.A., and D. Baltimore. 1988. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. *Cell.* 53:211–217.
12. Henkel, T., T. Machleidt, I. Alkalay, Y. Ben-Neriah, M. Krönke, and P.A. Baueuerle. 1993. Rapid proteolytic degradation of IkB-α induced by stimulation of cells with phorbol ester, cytokines and liposaccharides is a necessary step in the activation of NF-kB. *Nature ( Lond.)*. 365:182–184.
13. Beg, A.A., T.S. Finco, P.V. Nantermet, and A.S. Baldwin, Jr. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkB-α: a mechanism for NF-kB activation. *Mol. Cell. Biol.* 13:3301–3310.
14. Traenckner, E.B.-M., S. Wilk, and P.A. Baueuerle. 1994. A proteasome inhibitor prevents activation of NF-kB and stabilizes a newly phosphorylated form of IkB-α that is still bound to NF-kB. *EMBO (Eur. Mol. Biol. Organ.)* J. 13:5433–5441.
15. Sun, S.-C., P.A. Ganchi, C. Béraud, D.W. Ballard, and W.C. Greene. 1994. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. *Proc. Natl. Acad. Sci. USA.* 87:1346–1350.
16. Traenckner, E.B.-M., H.L. Pahl, T. Henkel, K.N. Schmidt, S. Wilk, and P.A. Baueuerle. 1995. Phosphorylation of human IkB-α on serine 32 and 36 controls IkB-α proteolysis and NF-kB activation in response to diverse stimuli. *EMBO (Eur. Mol. Biol. Organ.)* J. 14:2876–2883.
17. Grimm, S., and P.A. Baueuerle. 1993. The inducible transcription factor NF-kappa B: structure–function relationship of its protein subunits. *Biochem. J.* 290:297–308.
18. Sha, W.C., H.-C. Liou, E.L. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-kB leads to multifocal defects in immune responses. *Cell.* 80:321–330.
19. Beg, A.A., W.C. Sha, R.T. Bronson, S. Gosh, and D. Baltimore. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kB. *Nature ( Lond.)*. 376:167–170.
20. Köntgen, F., R.J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity and interleukin-2 expression. *Genes & Dev.* 9:1965–1977.
21. Rao, A. 1994. NFATp, a transcription factor required for the coordinate induction of several lymphokine genes. *Immunol. Today.* 15:274–281.
22. Rao, A. 1995. NFATp, a cyclosporin-sensitive transcription factor implicated in cytokine gene instruction. *J. Leukocyte Biol.* 57:536–542.
23. Crabtree, G.R., and N.A. Clipstone. 1994. Signal transduction between the plasma membrane and nucleus of T lymphocytes. *Annu. Rev. Biochem.* 63:1045–1083.
24. Liu, J., J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weissman, and S.L. Schreiber. 1991. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. *Cell.* 66:807–815.
25. McCaffrey, P.G., C. Luo, T.K. Kerppola, J. Jain, T.M. Bandalian, A.M. Ho, E. Burgeon, W.S. Lane, J.L. Lambert, T. Curran et al. 1993. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. *Science (Wash. DC).* 262:750–754.
26. Hall, B.M. 1982. Immunosuppression in renal transplantation. *Med. J. Austr.* 2:415–418.
27. White, D.J. 1982. Concanavalin: clinical pharmacology and therapeutic potential. *Drugs.* 24:322–334.
28. Bowman, H., and T.W. Lenard. 1992. Immunosuppressive drugs (review). *Br. J. Hosp. Med.* 48:570–573.
29. Levy, D.E., D.S. Kessler, R. Pine, and J.E. Darnell, Jr. 1989. Cytoplasmic activation of ISGF-3, the positive regulator of interferon-α–stimulated transcription, reconstituted in vitro. *Genes. Dev.* 3:1362–1371.
30. Darnell, J.F., Jr., I.M. Kerr, and G.R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. *Science (Wash. DC).* 264:1415–1421.
31. Sadowski, H.B., K. Shuai, J.E. Darnell, Jr., and M.Z. Gilman. 1993. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. *Science (Wash. DC).* 261:1739–1744.
32. Silvernoinen, O., C. Schindler, J. Schlessinger, and D.E. Levy. 1993. Ras-independent growth factor signalling by transcription factor tyrosine phosphorylation. *Science (Wash. DC).* 261:1736–1739.
33. Ruff-Jamison, S., K. Chen, and S. Cohen. 1995. Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. *Proc. Natl. Acad. Sci. USA.* 92:4215–4218.
34. Bacon, C.M., E.F. Petricoin III, J.R. Ortaldo, R.C. Rees, A.C. Lamer, J.A. Johnston, and J.J. O'Shea. 1995. IL-12 induces tyrosine phosphorylation and activation of Stat 4 in human lymphocytes. *Proc. Natl. Acad. Sci. USA.* 92:7303–7311.
35. Kotanides, H., M. Moczynega, M.F. White, and N.C. Reich. 1995. Characterization of the interleukin-4 nuclear activated factor/STAT and its activation independent of the insulin receptor substrate proteins. *J. Biol. Chem.* 270:19481–19486.
36. Frank, D.A., M.J. Robertson, A. Bonni, J. Ritz, and M.E. Greenberg. 1995. Interleukin-2 signalling involves the phosphorylation of Stat proteins. *Proc. Natl. Acad. Sci. USA.* 92:7779–7783.
37. Ledebur H.C., and T.P. Parks. 1995. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. *J. Biol. Chem.* 270:933–943.
38. Hou, J., V. Baichwal, and Z. Cao. 1994. Regulatory elements and transcription factors controlling basal and cytokine-induced expression of the gene encoding intercellular adhesion molecule 1. *Proc. Natl. Acad. Sci. USA.* 91:11641–11645.
39. van de Stolpe, A., E. Caldenhoven, B.G. Stade, L. Koenderman, J.P. Raaijmakers, J.P. Johnson, and P.T. van der Saag. 1994. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor-α mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. J. Biol. Chem. 269:6185–6192.

40. Kieran, M., V. Blank, F. Logeat, J. Vandekerckhove, F. Lottspeich, O. Le Bail, M.R. Urban, P. Kourilsky, P.A. Baeuerle, and A. Israel. 1990. The DNA binding subunit of NF-kappa B is identical to factor KBF-1 and homologous to the rel oncogene product. Cell. 62:1007–1018.

41. Li-Weber, M., H. Krafft, and P.H. Krammer. 1993. A novel enhancer element in the human IL-4 promoter is suppressed by a position-independent silencer. J. Immunol. 151:1371–1382.

42. Reich, N.C., B. Evans, D.E. Levy, D.E. Fahey, E. Knight, and J.E. Darnell. 1987. Interferon-induced transcription of a gene encoding a 15 kDa protein depends on an upstream enhancer element. Proc. Natl. Acad. Sci. USA. 84:6394–6398.

43. Brown, K., T. Kanno, G. Franzoso, and U. Siebenlist. 1993. Mutual regulation of the transcriptional activator NF-κB and its inhibitor IκB-α. Proc. Natl. Acad. Sci. USA. 90:2532–2536.

44. Safe, S., and A. Taylor. 1970. Sporidesmins. X. Synthesis of polysulfides by reaction of dihydrogen disulfide with disulfides and thiols. J. Chem. Soc. 3:432–435.

45. Müllbacher, A., P. Waring, U. Tiwari-Palni, and R. Eichner. 1986. Structural relationship of epipolythiodioxopiperazines and their immunomodulating activity. Mol. Immunol. 23:231–235.

46. Levy, D.E., D.J. Lew, T. Decker, D.S. Kessler, and J.E. Darnell, Jr. 1990. Synergistic interaction between interferon-α and interferon-γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO (Eur. Mol. Biol. Organ.) J. 9:1105–1111.

47. Pine, R., A. Canova, and C. Schindler. 1994. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFNa and IFNγ, and is likely to autoregulate the p91 gene. EMBO (Eur. Mol. Biol. Organ.) J. 13:158–167.

48. Wiegmann, K., S. Schütze, E. Kampen, A. Himmler, T. Machleidt, and M. Kröncke. 1992. Human 55 kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 267:17997–18001.

49. Matthews, J.R., N. Wakasugi, J.-L. Virelizier, J. Yodoi, and R.T. Hay. 1992. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res. 30:3821–3830.

50. Kumar, S., A.B. Rabson, and C. Gelinas. 1992. The Rxx-RxRxxC motif conserved in all Rel/κB proteins is essential for the DNA-binding activity and reductase regulation of the v-Rel oncoprotein. Mol. Cell. Biol. 12:3094–3106.

51. Toledano, M.B., and W.J. Leonhard. 1991. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA. 88:4328–4332.

52. Eichner, R.D., P. Waring, A.M. Geue, A.W. Braithwaite, and A. Müllbacher. 1988. Gliotoxin causes oxidative damage to plasmid and cellular DNA. J. Biol. Chem. 263:3772–3777.

53. Urban, M.B., and P.A. Baeuerle. 1991. The role of the p50 and p65 subunits of NF-kappa B in the recognition of cognate sequences. New Biol. 3:279–288.

54. Chaw, A.C., D.M. Desai, and A. Weiss. 1994. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu. Rev. Immunol. 12:555–592.

55. Howe, L.R., and A. Weiss. 1995. Multiple kinases mediate T-cell-receptor signalling. TIBS (Trends Biochem. Sci.) 20:59–64.

56. Burch, P.A., J.E. Karp, W.G. Merz, J.E. Kuhlman, and E.K. Fishman. 1987. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5:1985–1993.

57. Schweizer, M., and C. Richter. 1994. Gliotoxin stimulates Ca2+ release from intact rat liver mitochondria. Biochemistry. 33:13401–13405.

58. Beaver, J.P., and P. Waring. 1994. Lack of correlation between early intracellular calcium ion rises and the onset of apoptosis in thymocytes. ImmunoL Cell Biol. 72:489–499.

59. Eichner, R.D., M. al Salami, R.P. Wood, and A. Müllbacher. 1986. The effect of gliotoxin upon macrophage function. Int. J. Immunopharmacol. 8:789–797.

60. Hoyos, B., D.W. Ballard, E. Böhnlein, M. Siekewitz, and W.C. Greene. 1989. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science (Wash. DC). 244:437–460.